

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.6	91.2	(33.3-198.5)	Male	8	4.6	172.8	(74.4-340.6)
Female	3	2.4	nc	(nc-nc)	Female	5	3.7	135.6	(43.7-316.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	34	27.7	122.8	(85.0-171.5)	Female	4	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	12	8.9	134.6	(69.5-235.1)	<u>Ovary</u>				
Female	9	8.1	111.0	(50.6-210.6)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	33	27.2	121.1	(83.4-170.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.9	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	91	94.9	95.9	(77.2-117.8)
Female	2	0.6	nc	(nc-nc)	Female	96	90.7	105.9	(85.8-129.3)
<u>Lung and Bronchus</u>									
Male	7	12.5	56.2	(22.5-115.7)					
Female	10	12.0	83.0	(39.7-152.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	19.5	113.1	(70.8-171.2)	Male	14	12.7	110.2	(60.2-184.9)
Female	4	8.0	nc	(nc-nc)	Female	22	10.9	201.7	(126.4-305.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	11.0	72.8	(31.3-143.4)
Female	74	81.2	91.2	(71.6-114.4)	Female	7	10.1	69.1	(27.7-142.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	10	8.0	124.3	(59.5-228.7)
<u>Colon / Rectum</u>					Female	2	3.9	nc	(nc-nc)
Male	30	25.3	118.5	(79.9-169.2)	<u>Ovary</u>				
Female	24	27.4	87.7	(56.2-130.5)	Female	11	7.8	140.8	(70.2-251.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.3	94.4	(30.4-220.3)	Male	3	6.2	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	6	7.1	84.1	(30.7-183.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	75	75.0	100.1	(78.7-125.4)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.7	nc	(nc-nc)
Male	12	10.5	114.6	(59.1-200.2)	Female	4	3.1	nc	(nc-nc)
Female	3	6.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.5	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	13.3	127.9	(74.5-204.8)
Male	8	6.8	117.3	(50.5-231.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.6	106.8	(39.0-232.4)	Female	11	18.1	60.7	(30.3-108.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.5	nc	(nc-nc)	Male	263	264.9	99.3	(87.7-112.1)
Female	4	2.0	nc	(nc-nc)	Female	273	278.8	97.9	(86.6-110.2)
<u>Lung and Bronchus</u>									
Male	40	35.8	111.7	(79.8-152.1)					
Female	45	38.4	117.1	(85.4-156.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	98	101.2	96.9	(78.7-118.1)	Male	82	61.6	133.1	(105.9-165.3)
Female	35	37.9	92.5	(64.4-128.6)	Female	59	49.6	118.9	(90.5-153.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	18.4	108.7	(66.3-167.8)	Male	17	15.9	106.7	(62.1-170.8)
Female	20	15.5	128.7	(78.6-198.8)	Female	9	12.4	72.4	(33.0-137.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.8	nc	(nc-nc)	Male	64	54.2	118.0	(90.9-150.7)
Female	464	364.4	127.3	(116.0-139.5)	Female	56	47.7	117.4	(88.7-152.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	14.6	47.9	(19.2-98.8)	Male	36	37.1	97.1	(68.0-134.4)
<u>Colon / Rectum</u>					Female	25	17.9	139.3	(90.1-205.6)
Male	101	127.2	79.4	(64.7-96.5)	<u>Ovary</u>				
Female	119	129.1	92.2	(76.4-110.3)	Female	42	35.7	117.7	(84.8-159.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	25.6	39.0	(18.7-71.8)	Male	34	31.4	108.3	(75.0-151.3)
Female	3	7.3	nc	(nc-nc)	Female	31	34.0	91.2	(62.0-129.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	7.8	77.1	(28.1-167.7)	Male	373	359.0	103.9	(93.6-115.0)
Female	2	6.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	24.1	87.3	(54.0-133.4)
Male	45	49.9	90.2	(65.8-120.6)	Female	11	14.6	75.3	(37.5-134.8)
Female	37	30.0	123.2	(86.7-169.8)	<u>Testis</u>				
<u>Larynx</u>					Male	16	11.6	137.5	(78.6-223.4)
Male	10	14.6	68.3	(32.7-125.7)	<u>Thyroid</u>				
Female	2	4.1	nc	(nc-nc)	Male	27	17.7	152.3	(100.3-221.5)
<u>Leukemia</u>					Female	92	58.5	157.4	(126.9-193.0)
Male	27	34.6	78.0	(51.4-113.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	24	26.5	90.4	(57.9-134.5)	Female	93	81.2	114.5	(92.4-140.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	25.8	77.4	(47.3-119.6)	Male	1213	1304.7	93.0	(87.8-98.4)
Female	8	9.3	86.1	(37.1-169.7)	Female	1386	1284.5	107.9	(102.3-113.7)
<u>Lung and Bronchus</u>									
Male	97	181.8	53.3	(43.3-65.1)					
Female	144	182.3	79.0	(66.6-93.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.4	107.5	(46.3-211.8)	Male	7	6.6	105.7	(42.3-217.8)
Female	3	1.8	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	6	5.5	108.2	(39.5-235.5)
Female	36	26.5	135.8	(95.1-188.0)	Female	5	2.7	185.9	(59.9-433.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	10	11.2	89.2	(42.7-164.0)	<u>Ovary</u>				
Female	6	6.5	92.0	(33.6-200.3)	Female	2	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	5	2.6	191.8	(61.8-447.5)
Female	2	0.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	47	34.2	137.4	(100.9-182.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	8	5.4	147.0	(63.3-289.6)	Female	1	0.7	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	11	5.3	207.1	(103.2-370.5)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.6	nc	(nc-nc)	Female	12	5.7	209.5	(108.1-366.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	2.8	210.9	(77.0-459.0)	Male	138	123.1	112.1	(94.2-132.4)
Female	0	0.5	nc	(nc-nc)	Female	111	81.7	135.9	(111.8-163.6)
<u>Lung and Bronchus</u>									
Male	9	14.5	61.9	(28.3-117.5)					
Female	10	9.6	103.6	(49.6-190.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	17.2	139.1	(89.1-207.0)	Male	11	10.2	107.8	(53.8-192.9)
Female	4	7.6	nc	(nc-nc)	Female	3	8.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	9.0	nc	(nc-nc)
Female	49	63.5	77.2	(57.1-102.0)	Female	6	9.2	65.0	(23.7-141.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	8	6.0	134.4	(57.9-264.8)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	19	21.1	89.9	(54.1-140.4)	<u>Ovary</u>				
Female	29	25.5	113.5	(76.0-163.1)	Female	5	6.4	77.7	(25.0-181.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.3	187.0	(80.5-368.5)	Male	9	5.3	170.0	(77.6-322.7)
Female	5	1.5	335.5	(108.1-783.0)	Female	10	6.9	145.9	(69.8-268.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	71	60.2	117.9	(92.1-148.7)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.1	nc	(nc-nc)
Male	4	8.2	nc	(nc-nc)	Female	10	2.9	339.5	(162.5-624.4)
Female	5	5.6	89.3	(28.8-208.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.2	65.1	(23.8-141.7)
Male	4	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.1	116.7	(42.6-254.0)	Female	16	14.2	112.5	(64.3-182.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.2	nc	(nc-nc)	Male	249	218.8	113.8	(100.1-128.9)
Female	0	1.8	nc	(nc-nc)	Female	221	237.8	92.9	(81.1-106.0)
<u>Lung and Bronchus</u>									
Male	53	31.1	170.3	(127.5-222.7)					
Female	42	36.0	116.6	(84.0-157.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	28.1	131.6	(92.6-181.4)	Male	20	17.9	111.7	(68.2-172.6)
Female	16	11.6	137.9	(78.7-223.9)	Female	22	15.1	145.8	(91.4-220.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.6	107.2	(39.1-233.2)	Male	7	4.5	155.3	(62.2-319.9)
Female	4	4.8	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	14	15.8	88.7	(48.5-148.9)
Female	116	108.6	106.8	(88.3-128.1)	Female	14	14.6	96.1	(52.5-161.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	11	10.9	100.7	(50.2-180.1)
<u>Colon / Rectum</u>					Female	9	5.4	167.6	(76.5-318.2)
Male	34	36.1	94.3	(65.3-131.7)	<u>Ovary</u>				
Female	35	40.5	86.5	(60.3-120.3)	Female	11	10.7	103.1	(51.4-184.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	7.2	179.4	(95.4-306.8)	Male	5	8.8	56.7	(18.3-132.3)
Female	1	2.2	nc	(nc-nc)	Female	14	10.5	133.3	(72.8-223.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	116	100.7	115.2	(95.2-138.2)
Female	6	2.0	294.9	(107.7-641.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	6.8	132.9	(60.6-252.3)
Male	11	14.4	76.2	(38.0-136.4)	Female	3	4.6	nc	(nc-nc)
Female	6	8.9	67.1	(24.5-146.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	3.9	181.0	(72.5-372.9)
Male	4	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	9	5.4	165.9	(75.7-315.0)
<u>Leukemia</u>					Female	16	17.7	90.6	(51.8-147.2)
Male	8	10.2	78.5	(33.8-154.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.3	131.9	(65.8-236.0)	Female	19	23.5	80.8	(48.6-126.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.5	80.3	(29.3-174.8)	Male	407	370.9	109.7	(99.3-120.9)
Female	2	2.9	nc	(nc-nc)	Female	410	388.2	105.6	(95.6-116.4)
<u>Lung and Bronchus</u>									
Male	50	50.3	99.4	(73.7-131.0)					
Female	54	54.0	100.1	(75.2-130.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	22.9	56.8	(30.2-97.2)	Male	28	16.2	172.5	(114.6-249.4)
Female	8	8.6	93.3	(40.2-183.9)	Female	18	13.9	129.3	(76.6-204.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.4	93.4	(30.1-218.0)	Male	1	3.8	nc	(nc-nc)
Female	5	4.3	115.2	(37.1-268.8)	Female	5	2.9	175.0	(56.4-408.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	13	14.0	92.9	(49.4-158.8)
Female	111	96.9	114.5	(94.2-137.9)	Female	8	11.5	69.4	(29.9-136.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.6	nc	(nc-nc)	Male	8	10.2	78.6	(33.9-154.9)
<u>Colon / Rectum</u>					Female	6	4.6	131.7	(48.1-286.7)
Male	32	30.5	104.8	(71.6-147.9)	<u>Ovary</u>				
Female	33	29.6	111.5	(76.7-156.6)	Female	7	9.2	76.1	(30.5-156.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.4	nc	(nc-nc)	Male	5	7.4	67.4	(21.7-157.2)
Female	3	1.6	nc	(nc-nc)	Female	8	7.6	105.0	(45.2-207.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	95	90.4	105.1	(85.0-128.5)
Female	0	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.7	nc	(nc-nc)
Male	10	13.2	75.8	(36.3-139.4)	Female	0	3.3	nc	(nc-nc)
Female	7	7.6	92.6	(37.1-190.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.6	109.7	(35.4-256.0)
Male	6	3.7	162.5	(59.4-353.8)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	20	18.6	107.3	(65.5-165.6)
Male	8	8.8	90.9	(39.1-179.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.7	89.1	(32.5-193.9)	Female	20	21.2	94.3	(57.6-145.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	6.8	118.0	(50.8-232.5)	Male	330	325.9	101.2	(90.6-112.8)
Female	0	2.2	nc	(nc-nc)	Female	336	325.6	103.2	(92.5-114.8)
<u>Lung and Bronchus</u>									
Male	52	42.5	122.3	(91.3-160.3)					
Female	40	42.5	94.2	(67.3-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	17	18.5	91.8	(53.4-147.0)	Female	3	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	7	6.5	107.8	(43.2-222.1)	<u>Ovary</u>				
Female	6	6.1	98.7	(36.1-214.9)	Female	0	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	18.5	70.2	(37.3-120.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.1	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	48	67.7	70.9	(52.3-94.1)
Female	0	0.5	nc	(nc-nc)	Female	52	64.0	81.2	(60.7-106.5)
<u>Lung and Bronchus</u>									
Male	6	9.3	64.7	(23.6-140.9)					
Female	6	9.1	66.2	(24.2-144.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	13.0	138.7	(82.2-219.2)	Male	11	9.1	120.9	(60.3-216.3)
Female	8	4.6	175.5	(75.6-345.8)	Female	8	7.1	113.3	(48.8-223.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.8	141.4	(70.5-253.0)
Female	62	52.3	118.5	(90.9-151.9)	Female	9	6.1	148.4	(67.7-281.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.4	nc	(nc-nc)
Male	24	17.3	138.6	(88.8-206.2)	<u>Ovary</u>				
Female	12	15.3	78.3	(40.4-136.8)	Female	6	4.9	122.0	(44.5-265.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.0	124.6	(40.1-290.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	62	54.1	114.6	(87.8-146.9)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.2	nc	(nc-nc)
Male	10	7.6	131.5	(62.9-241.8)	Female	1	1.7	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	12	9.3	128.5	(66.3-224.5)
Male	5	4.8	103.1	(33.2-240.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.5	nc	(nc-nc)	Female	7	11.8	59.5	(23.8-122.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.9	nc	(nc-nc)	Male	212	187.1	113.3	(98.6-129.6)
Female	2	1.2	nc	(nc-nc)	Female	179	172.9	103.5	(88.9-119.9)
<u>Lung and Bronchus</u>									
Male	23	24.8	92.9	(58.8-139.3)					
Female	15	23.2	64.6	(36.1-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	30.4	78.9	(50.5-117.3)	Male	17	19.0	89.3	(52.0-142.9)
Female	9	12.7	71.0	(32.4-134.8)	Female	13	17.3	75.2	(40.0-128.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	87.8	(28.3-205.0)	Male	8	4.8	165.1	(71.1-325.3)
Female	8	5.3	151.5	(65.3-298.6)	Female	6	4.1	145.2	(53.0-316.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	16.7	108.0	(64.0-170.7)
Female	119	117.1	101.6	(84.2-121.6)	Female	16	16.1	99.6	(56.9-161.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.0	100.8	(32.5-235.1)	Male	8	11.6	69.1	(29.7-136.1)
<u>Colon / Rectum</u>					Female	5	5.9	84.2	(27.1-196.5)
Male	38	38.7	98.2	(69.5-134.8)	<u>Ovary</u>				
Female	40	44.3	90.3	(64.5-123.0)	Female	16	11.8	136.0	(77.7-220.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	7.9	178.2	(97.3-299.0)	Male	9	9.5	94.6	(43.1-179.5)
Female	4	2.4	nc	(nc-nc)	Female	18	11.5	156.9	(92.9-248.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.7	nc	(nc-nc)	Male	109	109.5	99.5	(81.7-120.0)
Female	1	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	7.3	nc	(nc-nc)
Male	16	15.4	103.9	(59.4-168.7)	Female	4	5.1	nc	(nc-nc)
Female	9	9.7	92.9	(42.4-176.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.2	119.0	(38.3-277.7)
Male	2	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<u>Leukemia</u>					Female	12	20.3	59.1	(30.5-103.2)
Male	7	10.5	66.9	(26.8-137.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.0	88.8	(38.2-175.0)	Female	29	25.6	113.3	(75.9-162.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	8.0	124.4	(59.6-228.9)	Male	368	398.8	92.3	(83.1-102.2)
Female	0	3.1	nc	(nc-nc)	Female	399	424.9	93.9	(84.9-103.6)
<u>Lung and Bronchus</u>									
Male	40	54.8	73.0	(52.2-99.4)					
Female	46	58.6	78.5	(57.5-104.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.0	91.3	(45.5-163.4)	Male	6	8.8	68.2	(24.9-148.4)
Female	5	4.3	115.1	(37.1-268.7)	Female	10	7.2	139.1	(66.6-255.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	5	7.5	66.5	(21.4-155.3)
Female	51	52.3	97.5	(72.6-128.2)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	2.4	208.5	(67.2-486.6)
Male	15	16.5	91.1	(50.9-150.2)	<u>Ovary</u>				
Female	29	14.9	195.2	(130.7-280.3)	Female	3	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	6	4.0	150.4	(54.9-327.4)
Female	1	0.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	59	51.3	114.9	(87.5-148.2)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.0	166.1	(53.5-387.6)
Male	3	7.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.2	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.8	50.9	(16.4-118.8)
Male	5	4.7	107.2	(34.5-250.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.4	nc	(nc-nc)	Female	8	11.6	69.2	(29.8-136.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.8	nc	(nc-nc)	Male	167	178.3	93.7	(80.0-109.0)
Female	0	1.1	nc	(nc-nc)	Female	167	170.5	97.9	(83.6-114.0)
<u>Lung and Bronchus</u>									
Male	21	23.1	90.8	(56.2-138.8)					
Female	17	22.1	76.9	(44.8-123.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.4	104.1	(58.2-171.7)	Male	9	9.2	98.2	(44.8-186.5)
Female	5	6.1	82.1	(26.5-191.7)	Female	3	7.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	8.1	124.0	(59.4-228.1)
Female	62	55.8	111.0	(85.1-142.3)	Female	11	7.6	144.9	(72.2-259.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	7	5.5	126.6	(50.7-260.8)
<u>Colon / Rectum</u>					Female	4	2.8	nc	(nc-nc)
Male	21	18.4	114.3	(70.7-174.8)	<u>Ovary</u>				
Female	21	21.2	99.0	(61.3-151.4)	Female	6	5.5	108.8	(39.7-236.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.7	135.6	(43.7-316.5)	Male	6	4.5	132.9	(48.5-289.4)
Female	1	1.2	nc	(nc-nc)	Female	5	5.5	90.7	(29.2-211.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.3	nc	(nc-nc)	Male	61	51.1	119.4	(91.3-153.4)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.5	nc	(nc-nc)
Male	6	7.4	81.4	(29.7-177.2)	Female	2	2.5	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	9.2	130.9	(67.5-228.6)
Male	8	5.2	153.9	(66.3-303.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.4	nc	(nc-nc)	Female	11	12.1	90.8	(45.3-162.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.8	132.6	(42.7-309.5)	Male	208	189.2	109.9	(95.5-125.9)
Female	1	1.5	nc	(nc-nc)	Female	207	201.8	102.6	(89.1-117.6)
<u>Lung and Bronchus</u>									
Male	23	25.8	89.3	(56.6-134.0)					
Female	35	28.1	124.7	(86.8-173.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	11	13.4	81.8	(40.8-146.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.4	137.4	(50.2-299.1)	Female	2	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	14.2	161.9	(102.6-242.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	5	3.0	165.3	(53.3-385.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	50	49.7	100.6	(74.7-132.6)
Female	0	0.3	nc	(nc-nc)	Female	40	45.9	87.2	(62.3-118.7)
<u>Lung and Bronchus</u>									
Male	5	6.7	74.4	(24.0-173.6)					
Female	3	6.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	13.0	77.2	(37.0-142.0)	Male	12	9.7	123.7	(63.8-216.1)
Female	4	5.1	nc	(nc-nc)	Female	16	8.8	182.2	(104.1-296.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	8.4	59.9	(19.3-139.7)
Female	59	59.0	100.0	(76.1-129.0)	Female	6	7.0	85.7	(31.3-186.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.9	nc	(nc-nc)	Male	5	6.2	80.4	(25.9-187.7)
<u>Colon / Rectum</u>					Female	3	2.8	nc	(nc-nc)
Male	31	17.8	174.3	(118.4-247.4)	<u>Ovary</u>				
Female	16	17.8	89.8	(51.3-145.8)	Female	6	5.6	106.5	(38.9-231.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.8	159.1	(58.1-346.4)	Male	6	4.3	140.2	(51.2-305.3)
Female	2	1.0	nc	(nc-nc)	Female	1	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	59	53.4	110.5	(84.1-142.6)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.3	nc	(nc-nc)
Male	10	7.9	126.6	(60.6-232.9)	Female	1	2.0	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.0	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.0	91.4	(45.6-163.6)
Male	5	5.3	94.5	(30.5-220.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.2	nc	(nc-nc)	Female	13	12.9	101.1	(53.8-173.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.1	171.3	(68.6-353.0)	Male	224	191.9	116.7	(101.9-133.1)
Female	0	1.3	nc	(nc-nc)	Female	195	198.2	98.4	(85.1-113.2)
<u>Lung and Bronchus</u>									
Male	34	24.3	140.0	(96.9-195.6)					
Female	22	24.8	88.7	(55.5-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	11.7	128.3	(71.8-211.7)	Male	15	7.7	194.6	(108.9-321.0)
Female	2	4.3	nc	(nc-nc)	Female	10	5.8	170.9	(81.8-314.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	37	44.5	83.1	(58.5-114.6)	Female	5	5.5	91.5	(29.5-213.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	5.0	139.7	(56.0-287.9)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	19	15.3	124.0	(74.6-193.7)	<u>Ovary</u>				
Female	18	14.7	122.7	(72.7-194.0)	Female	7	4.3	163.7	(65.6-337.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	46	47.3	97.2	(71.1-129.6)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	6	6.4	93.1	(34.0-202.7)	Female	1	1.7	nc	(nc-nc)
Female	5	3.5	141.9	(45.7-331.1)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.1	140.3	(67.2-258.0)
Male	7	4.2	167.9	(67.3-345.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.1	227.2	(91.0-468.2)	Female	7	10.1	69.2	(27.7-142.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.4	nc	(nc-nc)	Male	166	162.5	102.2	(87.2-118.9)
Female	2	1.1	nc	(nc-nc)	Female	154	151.3	101.8	(86.3-119.2)
<u>Lung and Bronchus</u>									
Male	19	21.8	87.0	(52.3-135.8)					
Female	23	20.6	111.5	(70.6-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	36.2	74.6	(49.2-108.6)	Male	24	21.7	110.8	(71.0-164.9)
Female	15	14.5	103.4	(57.8-170.6)	Female	20	17.6	113.4	(69.2-175.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	139.3	(63.6-264.5)	Male	3	5.6	nc	(nc-nc)
Female	9	5.6	160.3	(73.2-304.4)	Female	5	4.7	107.1	(34.5-249.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	19.1	120.7	(76.5-181.1)
Female	131	128.9	101.7	(85.0-120.6)	Female	14	17.8	78.7	(43.0-132.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.1	138.4	(55.4-285.1)	Male	14	12.6	110.7	(60.5-185.8)
<u>Colon / Rectum</u>					Female	3	6.5	nc	(nc-nc)
Male	50	44.6	112.2	(83.2-147.9)	<u>Ovary</u>				
Female	49	48.7	100.7	(74.5-133.1)	Female	18	12.8	140.4	(83.2-221.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.0	122.1	(60.9-218.5)	Male	12	11.1	107.7	(55.6-188.2)
Female	2	2.8	nc	(nc-nc)	Female	11	13.0	84.8	(42.3-151.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	109	126.1	86.4	(71.0-104.3)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	8.5	105.5	(48.1-200.2)
Male	20	17.4	114.6	(70.0-177.0)	Female	9	5.6	161.1	(73.5-305.8)
Female	8	11.1	72.3	(31.1-142.5)	<u>Testis</u>				
<u>Larynx</u>					Male	11	4.3	253.6	(126.4-453.8)
Male	10	5.1	194.6	(93.2-358.0)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
<u>Leukemia</u>					Female	19	19.9	95.7	(57.6-149.4)
Male	12	12.2	98.4	(50.8-172.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.9	100.7	(48.2-185.3)	Female	32	28.9	110.8	(75.8-156.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.8	79.4	(31.8-163.5)	Male	466	460.2	101.3	(92.3-110.9)
Female	2	3.5	nc	(nc-nc)	Female	503	469.3	107.2	(98.0-117.0)
<u>Lung and Bronchus</u>									
Male	72	65.0	110.7	(86.6-139.4)					
Female	92	69.3	132.7	(107.0-162.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.2	168.2	(67.4-346.6)	Male	4	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	5	2.3	214.0	(69.0-499.5)
Female	13	16.8	77.5	(41.2-132.5)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	5	5.3	93.8	(30.2-219.0)	<u>Ovary</u>				
Female	5	5.9	85.2	(27.4-198.7)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	1.6	318.5	(102.6-743.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	25	15.6	159.8	(103.4-235.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.7	188.6	(60.8-440.2)
Male	4	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.1	nc	(nc-nc)	Male	76	56.1	135.6	(106.8-169.7)
Female	0	0.4	nc	(nc-nc)	Female	55	59.3	92.7	(69.8-120.7)
<u>Lung and Bronchus</u>									
Male	8	7.7	104.1	(44.8-205.1)					
Female	5	8.7	57.6	(18.6-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	8	6.2	129.9	(56.0-256.1)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	6	6.2	97.4	(35.6-211.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	22.1	103.9	(65.8-155.9)
Female	0	0.1	nc	(nc-nc)	Female	17	19.1	89.1	(51.9-142.7)
<u>Lung and Bronchus</u>									
Male	5	2.8	177.5	(57.2-414.1)					
Female	0	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	8.5	177.4	(99.2-292.6)	Male	4	5.4	nc	(nc-nc)
Female	5	3.2	157.8	(50.9-368.4)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	24	31.3	76.7	(49.1-114.2)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	14	10.7	130.2	(71.1-218.5)	<u>Ovary</u>				
Female	7	10.6	65.7	(26.3-135.5)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	27	32.4	83.3	(54.9-121.2)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.2	96.9	(31.2-226.2)
Male	3	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	11	7.1	154.0	(76.8-275.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.3	nc	(nc-nc)	Male	109	113.8	95.7	(78.6-115.5)
Female	0	0.8	nc	(nc-nc)	Female	92	109.5	84.1	(67.8-103.1)
<u>Lung and Bronchus</u>									
Male	21	15.7	134.0	(82.9-204.9)					
Female	17	15.5	109.5	(63.8-175.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	16.9	130.4	(81.7-197.4)	Male	11	8.6	127.2	(63.4-227.7)
Female	9	6.0	150.2	(68.6-285.2)	Female	8	5.7	140.6	(60.5-277.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.7	90.9	(36.4-187.3)
Female	59	45.2	130.4	(99.3-168.2)	Female	8	6.9	115.4	(49.7-227.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	4.8	126.0	(46.0-274.2)
<u>Colon / Rectum</u>					Female	4	2.4	nc	(nc-nc)
Male	18	19.6	92.0	(54.5-145.5)	<u>Ovary</u>				
Female	18	19.6	91.6	(54.3-144.8)	Female	7	4.6	150.7	(60.4-310.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.8	nc	(nc-nc)	Male	6	5.0	119.9	(43.8-261.0)
Female	2	1.2	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	80	54.0	148.1	(117.5-184.4)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.8	nc	(nc-nc)
Male	7	7.0	100.5	(40.3-207.1)	Female	1	2.3	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.1	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.6	nc	(nc-nc)	Female	12	10.4	115.1	(59.4-201.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.5	nc	(nc-nc)	Male	215	195.9	109.8	(95.6-125.5)
Female	0	1.4	nc	(nc-nc)	Female	182	174.1	104.5	(89.9-120.9)
<u>Lung and Bronchus</u>									
Male	16	29.8	53.7	(30.7-87.1)					
Female	17	28.4	59.9	(34.9-96.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	10	7.9	126.0	(60.3-231.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	27.2	84.5	(53.5-126.7)
Female	1	0.1	nc	(nc-nc)	Female	15	19.3	77.6	(43.4-128.0)
<u>Lung and Bronchus</u>									
Male	2	3.8	nc	(nc-nc)					
Female	3	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.4	121.4	(67.9-200.2)	Male	4	8.5	nc	(nc-nc)
Female	8	4.5	177.1	(76.3-349.0)	Female	6	7.0	85.5	(31.2-186.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	5	2.2	227.7	(73.4-531.4)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	11	7.3	150.5	(75.0-269.3)
Female	48	50.1	95.9	(70.7-127.1)	Female	4	6.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	10	5.3	188.7	(90.4-347.1)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	14	16.3	85.9	(46.9-144.2)	<u>Ovary</u>				
Female	13	15.3	85.2	(45.3-145.8)	Female	3	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	36	48.3	74.5	(52.2-103.2)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	8	6.9	115.7	(49.8-227.9)	Female	0	1.7	nc	(nc-nc)
Female	5	4.0	125.7	(40.5-293.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.6	nc	(nc-nc)	Male	9	2.8	324.2	(147.9-615.4)
<u>Leukemia</u>					Female	3	9.2	nc	(nc-nc)
Male	5	4.6	108.3	(34.9-252.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.4	nc	(nc-nc)	Female	11	11.1	99.4	(49.5-177.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.6	nc	(nc-nc)	Male	191	172.8	110.6	(95.4-127.4)
Female	1	1.1	nc	(nc-nc)	Female	164	168.6	97.3	(82.9-113.3)
<u>Lung and Bronchus</u>									
Male	33	23.0	143.7	(98.9-201.9)					
Female	26	22.9	113.8	(74.3-166.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.4	104.2	(58.3-171.9)	Male	7	9.0	77.8	(31.2-160.3)
Female	4	6.0	nc	(nc-nc)	Female	10	7.5	133.7	(64.0-245.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.9	75.8	(27.7-165.0)
Female	48	54.4	88.2	(65.0-117.0)	Female	9	7.4	121.6	(55.5-230.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	7	5.4	129.1	(51.7-265.9)
<u>Colon / Rectum</u>					Female	2	2.7	nc	(nc-nc)
Male	12	18.2	65.9	(34.0-115.2)	<u>Ovary</u>				
Female	17	20.2	84.3	(49.1-135.1)	Female	2	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.7	nc	(nc-nc)	Male	5	4.5	111.2	(35.8-259.5)
Female	1	1.2	nc	(nc-nc)	Female	7	5.3	131.2	(52.6-270.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	46	51.9	88.6	(64.8-118.2)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	8	7.3	109.3	(47.0-215.3)	Female	0	2.3	nc	(nc-nc)
Female	6	4.6	130.2	(47.5-283.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.6	81.2	(32.5-167.2)
Male	3	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.1	nc	(nc-nc)	Female	13	12.0	108.7	(57.8-185.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.8	nc	(nc-nc)	Male	168	188.9	89.0	(76.0-103.5)
Female	1	1.4	nc	(nc-nc)	Female	173	196.0	88.3	(75.6-102.5)
<u>Lung and Bronchus</u>									
Male	27	26.2	103.2	(68.0-150.2)					
Female	23	28.4	81.0	(51.3-121.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	5.6	160.4	(73.2-304.5)	Male	3	3.4	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	20	17.4	115.0	(70.2-177.6)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	5	7.0	71.3	(23.0-166.5)	<u>Ovary</u>				
Female	6	5.5	108.5	(39.6-236.2)	Female	3	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	20.5	68.2	(37.3-114.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.2	nc	(nc-nc)	Female	7	3.9	179.0	(71.7-368.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	58	73.2	79.2	(60.1-102.4)
Female	1	0.4	nc	(nc-nc)	Female	55	59.6	92.3	(69.5-120.1)
<u>Lung and Bronchus</u>									
Male	7	10.3	68.1	(27.3-140.3)					
Female	4	8.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	78	66.0	118.2	(93.4-147.5)	Male	42	40.4	104.0	(75.0-140.6)
Female	35	25.5	137.2	(95.6-190.8)	Female	43	31.4	137.0	(99.1-184.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	12.0	108.4	(57.6-185.3)	Male	9	10.4	86.3	(39.4-163.9)
Female	4	10.0	nc	(nc-nc)	Female	11	8.3	132.5	(66.0-237.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.8	nc	(nc-nc)	Male	45	35.1	128.1	(93.4-171.4)
Female	242	236.3	102.4	(89.9-116.2)	Female	55	31.6	174.2	(131.2-226.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	9.0	88.8	(38.2-175.0)	Male	21	24.5	85.7	(53.0-130.9)
<u>Colon / Rectum</u>					Female	10	11.7	85.2	(40.8-156.7)
Male	95	82.4	115.3	(93.3-141.0)	<u>Ovary</u>				
Female	87	84.7	102.8	(82.3-126.8)	Female	20	23.2	86.0	(52.5-132.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	17.2	81.4	(44.5-136.6)	Male	25	20.6	121.2	(78.4-178.9)
Female	4	5.0	nc	(nc-nc)	Female	24	22.7	105.8	(67.7-157.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	4.9	nc	(nc-nc)	Male	235	246.1	95.5	(83.7-108.5)
Female	2	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	15.6	108.8	(63.3-174.2)
Male	49	33.2	147.8	(109.3-195.4)	Female	8	9.6	83.6	(36.0-164.7)
Female	32	20.1	159.5	(109.1-225.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	7.2	nc	(nc-nc)
Male	13	9.9	131.8	(70.1-225.4)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	9	11.6	77.6	(35.4-147.3)
<u>Leukemia</u>					Female	40	35.7	111.9	(79.9-152.4)
Male	41	22.2	184.7	(132.5-250.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	17.4	184.4	(126.1-260.3)	Female	67	53.8	124.6	(96.6-158.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	17.1	123.1	(76.2-188.3)	Male	954	865.2	110.3	(103.4-117.5)
Female	8	6.1	130.6	(56.2-257.3)	Female	1000	842.5	118.7	(111.5-126.3)
<u>Lung and Bronchus</u>									
Male	133	121.5	109.4	(91.6-129.7)					
Female	172	124.8	137.8	(118.0-160.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	6	6.0	99.3	(36.3-216.2)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.1	84.0	(30.7-182.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	24.4	69.6	(40.5-111.5)
Female	0	0.1	nc	(nc-nc)	Female	23	19.3	118.9	(75.4-178.5)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	2	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.7	122.4	(72.5-193.4)	Male	13	10.8	120.4	(64.0-205.9)
Female	4	5.2	nc	(nc-nc)	Female	9	8.7	103.6	(47.3-196.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	17	9.2	185.5	(108.0-297.0)
Female	75	62.9	119.2	(93.7-149.4)	Female	7	7.1	98.8	(39.6-203.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.9	nc	(nc-nc)	Male	11	7.1	155.1	(77.3-277.6)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	26	20.0	129.7	(84.7-190.1)	<u>Ovary</u>				
Female	13	17.3	75.1	(39.9-128.4)	Female	5	5.9	84.6	(27.3-197.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.4	nc	(nc-nc)	Male	5	4.9	102.1	(32.9-238.3)
Female	1	1.0	nc	(nc-nc)	Female	5	4.5	110.8	(35.7-258.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	77	64.5	119.3	(94.2-149.1)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.7	nc	(nc-nc)
Male	10	9.0	111.2	(53.3-204.6)	Female	2	1.9	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.7	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	18	11.9	151.1	(89.5-238.9)
Male	5	5.7	87.1	(28.1-203.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.1	nc	(nc-nc)	Female	16	14.4	111.3	(63.6-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	4.7	171.3	(73.8-337.5)	Male	258	219.9	117.3	(103.4-132.5)
Female	0	1.3	nc	(nc-nc)	Female	225	205.1	109.7	(95.8-125.0)
<u>Lung and Bronchus</u>									
Male	38	28.3	134.3	(95.0-184.3)					
Female	37	26.9	137.7	(97.0-189.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	7.7	180.9	(98.8-303.6)	Male	3	6.0	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	5.1	116.8	(42.7-254.3)
Female	45	36.8	122.4	(89.3-163.8)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	5	3.9	128.8	(41.5-300.5)
<u>Colon / Rectum</u>					Female	4	1.7	nc	(nc-nc)
Male	12	10.9	110.4	(57.0-192.9)	<u>Ovary</u>				
Female	5	10.3	48.5	(15.6-113.2)	Female	1	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	39	32.5	120.2	(85.4-164.3)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	2.0	304.6	(111.2-663.0)
Male	5	4.9	101.3	(32.6-236.4)	Female	2	1.1	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.2	83.1	(30.4-181.0)
Male	4	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.5	284.4	(113.9-586.0)	Female	6	8.0	75.3	(27.5-164.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	139	116.9	118.9	(99.9-140.4)
Female	3	0.8	nc	(nc-nc)	Female	127	119.4	106.4	(88.7-126.5)
<u>Lung and Bronchus</u>									
Male	19	14.7	128.8	(77.5-201.2)					
Female	16	15.0	106.5	(60.8-172.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	6	2.5	238.4	(87.0-518.8)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.4	148.5	(47.9-346.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	12.1	49.5	(18.1-107.7)
Female	0	0.0	nc	(nc-nc)	Female	11	7.9	139.8	(69.7-250.2)
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	10	6.0	167.9	(80.4-308.8)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	8	6.5	122.9	(52.9-242.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	22.2	134.9	(91.0-192.6)
Female	0	0.2	nc	(nc-nc)	Female	24	21.1	113.9	(73.0-169.5)
<u>Lung and Bronchus</u>									
Male	4	3.1	nc	(nc-nc)					
Female	3	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.4	130.5	(52.3-268.8)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	6.0	148.9	(68.0-282.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	21.5	83.5	(49.5-132.0)
Female	0	0.1	nc	(nc-nc)	Female	20	17.0	117.8	(71.9-181.9)
<u>Lung and Bronchus</u>									
Male	0	2.7	nc	(nc-nc)					
Female	4	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	58.5	119.7	(93.3-151.2)	Male	34	34.4	98.8	(68.4-138.1)
Female	18	23.7	76.1	(45.1-120.3)	Female	32	27.7	115.6	(79.0-163.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	10.2	157.2	(89.8-255.3)	Male	11	9.0	122.2	(60.9-218.6)
Female	4	8.9	nc	(nc-nc)	Female	5	7.6	65.4	(21.1-152.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	29	30.4	95.5	(64.0-137.2)
Female	226	205.0	110.3	(96.4-125.6)	Female	25	28.8	86.8	(56.2-128.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	7.7	91.1	(36.5-187.7)	Male	27	20.1	134.2	(88.4-195.2)
<u>Colon / Rectum</u>					Female	7	10.5	66.7	(26.7-137.3)
Male	92	71.7	128.4	(103.5-157.4)	<u>Ovary</u>				
Female	90	79.3	113.5	(91.2-139.5)	Female	15	20.5	73.2	(40.9-120.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	14.5	144.8	(89.6-221.4)	Male	18	17.9	100.3	(59.4-158.5)
Female	7	4.6	151.7	(60.8-312.6)	Female	24	21.3	112.9	(72.3-168.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.3	nc	(nc-nc)	Male	192	204.0	94.1	(81.3-108.4)
Female	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	13.7	72.8	(34.9-133.9)
Male	31	27.8	111.6	(75.8-158.3)	Female	5	9.1	54.9	(17.7-128.1)
Female	18	17.7	101.4	(60.1-160.3)	<u>Testis</u>				
<u>Larynx</u>					Male	12	6.4	188.9	(97.5-330.1)
Male	6	8.3	72.6	(26.5-158.0)	<u>Thyroid</u>				
Female	1	2.4	nc	(nc-nc)	Male	9	9.5	94.5	(43.1-179.4)
<u>Leukemia</u>					Female	23	30.1	76.3	(48.4-114.5)
Male	22	19.5	113.0	(70.8-171.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	15.9	75.3	(38.9-131.5)	Female	39	46.2	84.5	(60.1-115.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	14.2	148.3	(91.8-226.8)	Male	780	739.3	105.5	(98.2-113.2)
Female	10	5.6	177.5	(85.0-326.5)	Female	779	752.7	103.5	(96.4-111.0)
<u>Lung and Bronchus</u>									
Male	108	105.3	102.6	(84.1-123.8)					
Female	135	112.6	119.9	(100.5-141.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.1	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	11.5	113.4	(60.3-193.9)
Female	0	0.1	nc	(nc-nc)	Female	9	8.1	111.7	(51.0-212.0)
<u>Lung and Bronchus</u>									
Male	4	1.6	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.1	123.1	(58.9-226.4)	Male	2	5.4	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.6	150.5	(60.3-310.2)
Female	26	30.7	84.8	(55.4-124.3)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	6	3.4	178.9	(65.3-389.3)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	9	10.4	86.3	(39.4-163.8)	<u>Ovary</u>				
Female	9	9.6	93.3	(42.6-177.1)	Female	1	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	40	31.8	125.8	(89.8-171.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.3	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	13	7.0	186.7	(99.3-319.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	132	112.0	117.9	(98.6-139.8)
Female	0	0.7	nc	(nc-nc)	Female	92	104.8	87.8	(70.8-107.7)
<u>Lung and Bronchus</u>									
Male	20	15.2	131.4	(80.2-202.9)					
Female	16	14.8	108.2	(61.8-175.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	53.3	107.0	(81.0-138.6)	Male	62	35.6	174.4	(133.7-223.6)
Female	25	20.1	124.5	(80.5-183.7)	Female	49	28.6	171.1	(126.6-226.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.3	79.8	(36.4-151.4)	Male	14	8.7	160.3	(87.6-268.9)
Female	9	9.0	99.9	(45.6-189.7)	Female	8	6.7	120.0	(51.7-236.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	30	30.9	96.9	(65.4-138.4)
Female	258	206.9	124.7	(109.9-140.9)	Female	34	26.0	130.8	(90.5-182.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.8	90.8	(39.1-179.0)	Male	22	22.0	99.8	(62.6-151.2)
<u>Colon / Rectum</u>					Female	10	10.0	100.2	(48.0-184.3)
Male	82	69.6	117.9	(93.8-146.3)	<u>Ovary</u>				
Female	73	69.2	105.5	(82.7-132.7)	Female	22	20.0	110.0	(68.9-166.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	14.4	111.5	(63.7-181.1)	Male	16	17.0	94.3	(53.9-153.1)
Female	2	3.9	nc	(nc-nc)	Female	21	18.0	116.7	(72.2-178.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.4	110.5	(40.4-240.6)	Male	283	202.4	139.8	(124.0-157.1)
Female	10	3.9	254.0	(121.6-467.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	13.0	154.3	(94.2-238.3)
Male	34	28.8	118.0	(81.7-164.8)	Female	6	7.8	77.2	(28.2-168.1)
Female	31	16.6	186.8	(126.9-265.2)	<u>Testis</u>				
<u>Larynx</u>					Male	7	8.9	79.0	(31.6-162.7)
Male	12	8.3	145.5	(75.1-254.1)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	11	11.4	96.6	(48.2-172.9)
<u>Leukemia</u>					Female	40	35.5	112.7	(80.5-153.5)
Male	16	19.6	81.7	(46.7-132.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	24	14.8	162.1	(103.8-241.2)	Female	53	46.1	115.0	(86.2-150.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	14.9	113.8	(66.3-182.2)	Male	878	730.3	120.2	(112.4-128.5)
Female	7	5.1	138.4	(55.5-285.2)	Female	872	713.5	122.2	(114.2-130.6)
<u>Lung and Bronchus</u>									
Male	116	97.4	119.0	(98.4-142.8)					
Female	111	97.3	114.1	(93.8-137.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	5	1.7	298.3	(96.1-696.2)
Female	0	0.7	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	8	9.6	83.0	(35.8-163.6)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	10.0	149.8	(83.8-247.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	43	33.9	126.8	(91.8-170.8)
Female	1	0.2	nc	(nc-nc)	Female	29	30.3	95.8	(64.2-137.6)
<u>Lung and Bronchus</u>									
Male	3	4.3	nc	(nc-nc)					
Female	6	3.6	164.4	(60.0-357.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	13	12.6	103.2	(54.9-176.4)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	3.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	13.0	131.1	(76.3-209.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	5	2.7	183.6	(59.2-428.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	43	45.2	95.2	(68.9-128.2)
Female	0	0.2	nc	(nc-nc)	Female	34	39.2	86.7	(60.0-121.1)
<u>Lung and Bronchus</u>									
Male	6	5.8	103.9	(38.0-226.2)					
Female	0	4.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.1	158.3	(68.2-311.9)	Male	6	3.2	185.4	(67.7-403.4)
Female	1	1.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	2.8	214.4	(78.3-466.8)
Female	19	16.0	118.6	(71.4-185.2)	Female	0	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	6	2.0	305.0	(111.4-663.9)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	11	6.5	168.8	(84.1-302.0)	<u>Ovary</u>				
Female	3	6.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.4	nc	(nc-nc)	Male	16	18.2	88.2	(50.4-143.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.5	142.9	(46.1-333.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	1.4	367.6	(118.5-857.8)	Male	96	66.5	144.3	(116.9-176.2)
Female	0	0.4	nc	(nc-nc)	Female	53	56.9	93.1	(69.7-121.8)
<u>Lung and Bronchus</u>									
Male	10	9.1	109.8	(52.6-202.0)					
Female	12	8.1	148.9	(76.9-260.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	92	105.4	87.3	(70.4-107.0)	Male	65	65.4	99.3	(76.6-126.6)
Female	50	42.9	116.6	(86.6-153.8)	Female	58	54.9	105.7	(80.3-136.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	19.7	91.4	(54.1-144.4)	Male	15	16.6	90.5	(50.6-149.3)
Female	10	17.1	58.5	(28.0-107.5)	Female	14	13.9	100.6	(55.0-168.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	48	57.0	84.2	(62.1-111.7)
Female	366	392.8	93.2	(83.9-103.2)	Female	61	53.3	114.4	(87.5-146.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	16.1	137.0	(85.8-207.4)	Male	49	38.5	127.2	(94.1-168.1)
<u>Colon / Rectum</u>					Female	21	19.8	106.1	(65.6-162.1)
Male	129	131.7	97.9	(81.7-116.3)	<u>Ovary</u>				
Female	164	143.8	114.0	(97.3-132.9)	Female	46	38.9	118.3	(86.6-157.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	26.9	108.0	(72.3-155.1)	Male	29	32.7	88.6	(59.3-127.3)
Female	8	8.4	95.7	(41.2-188.6)	Female	34	38.3	88.8	(61.5-124.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	9.2	108.4	(51.9-199.3)	Male	311	379.8	81.9	(73.0-91.5)
Female	9	7.4	122.0	(55.7-231.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	37	25.1	147.5	(103.9-203.4)
Male	53	52.5	101.0	(75.6-132.1)	Female	14	16.4	85.4	(46.7-143.3)
Female	34	33.4	101.9	(70.6-142.4)	<u>Testis</u>				
<u>Larynx</u>					Male	9	15.1	59.6	(27.2-113.2)
Male	15	15.4	97.6	(54.6-161.0)	<u>Thyroid</u>				
Female	7	4.6	153.2	(61.4-315.7)	Male	15	19.5	76.9	(43.0-126.8)
<u>Leukemia</u>					Female	70	63.8	109.6	(85.5-138.5)
Male	33	36.1	91.5	(63.0-128.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	31	29.6	104.9	(71.2-148.9)	Female	93	88.2	105.5	(85.1-129.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	45	26.7	168.7	(123.1-225.8)	Male	1281	1374.4	93.2	(88.2-98.4)
Female	12	10.3	116.2	(60.0-203.0)	Female	1480	1417.8	104.4	(99.1-109.8)
<u>Lung and Bronchus</u>									
Male	177	191.4	92.5	(79.3-107.1)					
Female	236	206.8	114.1	(100.0-129.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	33.1	90.6	(61.1-129.4)	Male	15	21.5	69.8	(39.1-115.2)
Female	9	12.3	72.9	(33.3-138.4)	Female	15	17.7	84.9	(47.5-140.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.7	148.3	(71.0-272.8)	Male	5	5.3	93.6	(30.2-218.4)
Female	3	5.6	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	24	18.7	128.4	(82.3-191.1)
Female	129	126.9	101.7	(84.9-120.8)	Female	17	15.9	106.7	(62.1-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.5	91.1	(29.4-212.5)	Male	7	13.2	53.1	(21.3-109.4)
<u>Colon / Rectum</u>					Female	3	6.1	nc	(nc-nc)
Male	42	42.5	98.9	(71.3-133.7)	<u>Ovary</u>				
Female	51	41.6	122.5	(91.2-161.0)	Female	20	12.2	163.3	(99.7-252.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.8	102.1	(46.6-193.8)	Male	15	10.5	143.1	(80.0-236.1)
Female	1	2.4	nc	(nc-nc)	Female	17	11.0	154.9	(90.2-248.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	110	124.7	88.2	(72.5-106.4)
Female	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	8.0	87.7	(35.1-180.8)
Male	18	17.5	102.7	(60.8-162.2)	Female	13	4.7	278.0	(147.9-475.4)
Female	8	10.3	77.7	(33.5-153.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.9	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	7	6.7	104.9	(42.0-216.0)
<u>Leukemia</u>					Female	19	22.2	85.7	(51.6-133.8)
Male	10	11.9	84.3	(40.4-155.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.0	77.4	(31.0-159.4)	Female	39	28.3	137.6	(97.9-188.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.0	121.8	(60.7-217.9)	Male	455	447.0	101.8	(92.7-111.6)
Female	4	3.1	nc	(nc-nc)	Female	478	438.4	109.0	(99.5-119.3)
<u>Lung and Bronchus</u>									
Male	82	60.9	134.6	(107.0-167.1)					
Female	75	60.9	123.2	(96.9-154.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.7	101.9	(55.6-170.9)	Male	12	9.0	133.5	(68.9-233.3)
Female	1	5.2	nc	(nc-nc)	Female	8	7.4	107.7	(46.4-212.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.8	76.8	(28.0-167.2)
Female	55	54.2	101.5	(76.5-132.1)	Female	3	6.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.3	nc	(nc-nc)	Male	6	5.6	106.9	(39.0-232.6)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	20	17.8	112.5	(68.7-173.8)	<u>Ovary</u>				
Female	9	17.8	50.7	(23.1-96.2)	Female	7	5.2	133.9	(53.6-275.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.7	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	60	53.0	113.3	(86.4-145.8)
Female	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.3	nc	(nc-nc)
Male	12	7.4	162.4	(83.8-283.7)	Female	0	2.0	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	2.8	178.8	(57.6-417.4)
<u>Leukemia</u>					Female	9	9.2	97.4	(44.4-184.9)
Male	2	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	9	12.2	73.8	(33.7-140.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	3.8	156.4	(57.1-340.5)	Male	200	187.6	106.6	(92.3-122.4)
Female	1	1.3	nc	(nc-nc)	Female	165	186.4	88.5	(75.5-103.1)
<u>Lung and Bronchus</u>									
Male	23	25.4	90.5	(57.3-135.8)					
Female	27	25.9	104.4	(68.8-152.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	26.0	100.1	(65.4-146.7)	Male	20	16.5	121.0	(73.9-186.9)
Female	16	10.0	160.3	(91.6-260.4)	Female	13	13.2	98.2	(52.3-168.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	5.1	214.0	(106.7-382.9)	Male	2	4.2	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	14.4	83.2	(42.9-145.3)
Female	131	99.4	131.8	(110.2-156.4)	Female	13	12.6	103.1	(54.8-176.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.0	nc	(nc-nc)	Male	12	10.1	118.5	(61.1-207.0)
<u>Colon / Rectum</u>					Female	4	4.8	nc	(nc-nc)
Male	29	33.1	87.7	(58.7-126.0)	<u>Ovary</u>				
Female	56	33.5	167.0	(126.1-216.9)	Female	6	9.6	62.7	(22.9-136.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.9	72.8	(23.5-169.9)	Male	10	8.2	122.1	(58.4-224.5)
Female	3	1.9	nc	(nc-nc)	Female	11	8.9	123.7	(61.7-221.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.1	nc	(nc-nc)	Male	114	96.8	117.8	(97.2-141.5)
Female	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.2	112.3	(45.0-231.4)
Male	9	13.6	66.1	(30.2-125.5)	Female	7	3.8	185.2	(74.2-381.6)
Female	4	8.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.3	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	8	5.0	159.4	(68.6-314.1)
<u>Leukemia</u>					Female	26	16.0	162.5	(106.2-238.2)
Male	10	9.1	109.6	(52.5-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	7.1	126.8	(57.9-240.7)	Female	25	22.2	112.6	(72.8-166.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.0	100.5	(40.2-207.0)	Male	354	346.5	102.2	(91.8-113.4)
Female	3	2.4	nc	(nc-nc)	Female	404	344.6	117.2	(106.1-129.3)
<u>Lung and Bronchus</u>									
Male	44	47.9	91.9	(66.8-123.4)					
Female	40	49.0	81.6	(58.3-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.2	137.3	(75.0-230.5)	Male	10	7.4	135.8	(65.0-249.7)
Female	7	3.5	199.8	(80.1-411.8)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.3	111.4	(44.6-229.5)
Female	42	42.2	99.4	(71.7-134.4)	Female	5	4.7	105.5	(34.0-246.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	5	4.9	102.1	(32.9-238.2)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	12	13.9	86.1	(44.4-150.4)	<u>Ovary</u>				
Female	10	12.0	83.3	(39.9-153.2)	Female	5	3.9	126.9	(40.9-296.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.0	nc	(nc-nc)	Male	5	3.4	147.6	(47.6-344.4)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	59	43.4	135.8	(103.4-175.2)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.5	nc	(nc-nc)
Male	5	6.2	80.8	(26.0-188.6)	Female	2	1.3	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.7	77.5	(28.3-168.6)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.7	186.8	(60.2-435.9)	Female	10	9.4	106.5	(51.0-195.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.3	152.9	(49.3-356.7)	Male	160	150.0	106.7	(90.8-124.5)
Female	2	0.9	nc	(nc-nc)	Female	136	137.1	99.2	(83.2-117.3)
<u>Lung and Bronchus</u>									
Male	17	19.5	87.4	(50.9-139.9)					
Female	22	17.8	123.6	(77.4-187.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	53.7	93.0	(69.1-122.7)	Male	23	32.9	70.0	(44.4-105.0)
Female	30	20.9	143.7	(96.9-205.2)	Female	28	26.5	105.5	(70.1-152.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.1	99.5	(47.6-183.0)	Male	15	8.3	179.7	(100.5-296.4)
Female	8	8.5	94.3	(40.6-185.8)	Female	9	6.7	133.6	(60.9-253.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	31	28.8	107.7	(73.1-152.8)
Female	201	189.4	106.1	(92.0-121.8)	Female	34	25.9	131.2	(90.8-183.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	7.9	139.5	(69.5-249.6)	Male	19	19.0	99.8	(60.0-155.8)
<u>Colon / Rectum</u>					Female	8	9.5	83.9	(36.1-165.4)
Male	81	66.4	122.0	(96.9-151.7)	<u>Ovary</u>				
Female	62	69.8	88.9	(68.1-113.9)	Female	15	18.8	79.9	(44.7-131.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	13.5	51.8	(20.7-106.7)	Male	17	16.6	102.5	(59.7-164.1)
Female	2	4.1	nc	(nc-nc)	Female	16	18.6	86.1	(49.2-139.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	4.5	220.4	(105.5-405.4)	Male	154	190.0	81.0	(68.7-94.9)
Female	5	3.6	140.6	(45.3-328.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	12.7	118.1	(66.0-194.8)
Male	41	26.4	155.4	(111.5-210.9)	Female	8	8.0	100.4	(43.2-197.9)
Female	31	16.3	190.6	(129.5-270.5)	<u>Testis</u>				
<u>Larynx</u>					Male	10	7.4	135.1	(64.7-248.5)
Male	15	7.7	194.2	(108.6-320.3)	<u>Thyroid</u>				
Female	1	2.2	nc	(nc-nc)	Male	13	9.7	134.5	(71.6-230.1)
<u>Leukemia</u>					Female	29	31.0	93.4	(62.6-134.2)
Male	18	18.4	97.6	(57.8-154.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	14.6	109.3	(62.5-177.6)	Female	44	42.4	103.8	(75.4-139.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	13.2	143.7	(86.5-224.4)	Male	747	692.6	107.9	(100.3-115.9)
Female	7	5.0	139.3	(55.8-287.1)	Female	773	687.6	112.4	(104.6-120.6)
<u>Lung and Bronchus</u>									
Male	135	97.4	138.7	(116.3-164.1)					
Female	142	100.6	141.1	(118.8-166.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	10	8.1	123.5	(59.1-227.2)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	17	9.4	181.4	(105.6-290.5)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	36	31.1	115.6	(81.0-160.1)
Female	1	0.2	nc	(nc-nc)	Female	28	27.1	103.4	(68.7-149.5)
<u>Lung and Bronchus</u>									
Male	2	4.3	nc	(nc-nc)					
Female	0	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.6	151.8	(60.8-312.8)	Male	4	3.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	22	19.0	115.5	(72.4-174.9)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	2	6.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	5.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	25	19.8	126.6	(81.9-186.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.6	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	6	4.2	143.3	(52.3-311.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	66	68.6	96.3	(74.5-122.5)
Female	0	0.4	nc	(nc-nc)	Female	58	61.1	94.9	(72.0-122.7)
<u>Lung and Bronchus</u>									
Male	6	8.8	68.1	(24.9-148.2)					
Female	7	7.8	89.7	(35.9-184.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.6	102.4	(60.7-161.9)	Male	15	11.4	131.8	(73.7-217.4)
Female	11	7.2	152.4	(76.0-272.7)	Female	10	9.9	101.1	(48.4-185.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.5	nc	(nc-nc)	Male	9	9.9	90.9	(41.5-172.6)
Female	66	72.1	91.6	(70.8-116.5)	Female	6	9.2	65.2	(23.8-141.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	3.5	198.8	(79.6-409.6)
Male	28	22.4	125.1	(83.1-180.8)	<u>Ovary</u>				
Female	26	23.9	108.9	(71.1-159.6)	Female	9	7.0	128.2	(58.5-243.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	4.7	255.9	(132.1-447.1)	Male	4	5.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	13	6.4	203.7	(108.4-348.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	60	66.9	89.6	(68.4-115.4)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.2	nc	(nc-nc)
Male	18	9.3	193.3	(114.5-305.6)	Female	1	2.7	nc	(nc-nc)
Female	3	6.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	13	12.1	107.3	(57.1-183.5)
Male	8	6.3	126.9	(54.7-250.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.2	nc	(nc-nc)	Female	14	16.4	85.1	(46.5-142.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.7	126.7	(46.3-275.8)	Male	262	238.1	110.0	(97.1-124.2)
Female	2	1.8	nc	(nc-nc)	Female	269	251.5	107.0	(94.6-120.6)
<u>Lung and Bronchus</u>									
Male	36	32.7	110.2	(77.2-152.5)					
Female	54	36.1	149.5	(112.3-195.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	11.6	137.4	(78.5-223.1)	Male	11	6.8	161.2	(80.4-288.4)
Female	7	4.7	148.9	(59.7-306.9)	Female	7	5.5	127.4	(51.0-262.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	6.0	149.8	(68.3-284.3)
Female	41	42.6	96.3	(69.1-130.6)	Female	5	5.7	87.0	(28.0-203.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	24	14.5	165.5	(106.0-246.2)	<u>Ovary</u>				
Female	18	15.9	113.3	(67.1-179.0)	Female	7	4.2	167.0	(66.9-344.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.9	173.0	(55.7-403.7)	Male	4	3.6	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	6	4.2	141.8	(51.8-308.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	39	40.5	96.2	(68.4-131.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	1	5.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.0	100.5	(36.7-218.8)
Male	6	3.8	156.2	(57.1-340.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.1	nc	(nc-nc)	Female	13	9.6	135.1	(71.9-231.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.9	nc	(nc-nc)	Male	159	146.7	108.4	(92.2-126.6)
Female	1	1.1	nc	(nc-nc)	Female	157	152.2	103.2	(87.7-120.6)
<u>Lung and Bronchus</u>									
Male	21	20.7	101.4	(62.7-154.9)					
Female	20	22.5	88.9	(54.3-137.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	5	1.9	265.1	(85.4-618.5)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.9	100.9	(43.4-198.8)
Female	0	0.0	nc	(nc-nc)	Female	11	6.4	172.4	(85.9-308.5)
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.7	128.7	(47.0-280.2)	Male	2	3.4	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	2.9	204.1	(74.5-444.2)
Female	23	20.9	110.2	(69.8-165.3)	Female	5	2.4	204.2	(65.8-476.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	6	6.4	93.6	(34.2-203.7)	<u>Ovary</u>				
Female	5	6.5	77.0	(24.8-179.7)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.3	376.2	(121.2-877.8)	Male	0	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	18	18.7	96.3	(57.0-152.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	5	4.5	112.1	(36.1-261.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	71	67.7	104.9	(81.9-132.3)
Female	0	0.5	nc	(nc-nc)	Female	68	69.5	97.9	(76.0-124.1)
<u>Lung and Bronchus</u>									
Male	7	8.7	80.6	(32.3-166.0)					
Female	13	8.9	146.0	(77.6-249.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	17	17.5	97.3	(56.7-155.8)
Female	0	0.1	nc	(nc-nc)	Female	6	14.8	40.6	(14.8-88.3)
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;